Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215927 · ClinicalTrials.gov registry record · Phase 2
Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
A Phase 2 study, sponsored by Rohit Aggarwal, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03215927 is a Phase 2 study that has completed, run by Rohit Aggarwal, MD. The registered enrollment target is 20 participants.
The verdict
NCT03215927, a Phase 2 study, has completed, sponsored by Rohit Aggarwal, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
Interventions
- OTHER Placebo
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2023-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03215927
The ClinicalTrials.gov registry entry for NCT03215927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rohit Aggarwal, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03215927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03215927 about?
NCT03215927 is a clinical study titled "Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease". A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
What is the current status of trial NCT03215927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-01-01. Estimated completion is 2023-07-30.
What interventions are being tested in trial NCT03215927?
The interventions under investigation include: Placebo (OTHER), Abatacept (DRUG).
Who is sponsoring clinical trial NCT03215927?
This trial is sponsored by Rohit Aggarwal, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.